Risperidone May Worsen Fluoxetine-Treated OCD
J Clin Psychiatry 1998;59(5):255-256 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Sir: Several recent studies have suggested that risperidone may usefully augment serotonin reuptake inhibitor (SRI) therapy in refractory obsessive-compulsive disorder (OCD). One study found that 14 of 16 refractory OCD patients experienced substantial improvement in obsessive-compulsive symptoms within 3 weeks of the initiation of an SRI-risperidone combination; indeed, certain patients improved dramatically within days. A second study reported that 7 of 14 OCD patients responded with the addition of risperidone after having failed to respond to SRI therapy alone. A retrospective chart review discovered that 8 patients with OCD who had failed an SRI trial responded within a month of supplementation with risperidone.